These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 7995043)
1. Overview of currently used chemosensitivity test systems in gynecologic malignancies and breast cancer. Köchli OR; Sevin BU; Averette HE; Haller U Contrib Gynecol Obstet; 1994; 19():12-23. PubMed ID: 7995043 [No Abstract] [Full Text] [Related]
2. The fluorescent cytoprint assay in gynecological malignancies and breast cancer. Methodology and results. Blackman KE; Fingert HJ; Fuller AF; Meitner PA Contrib Gynecol Obstet; 1994; 19():53-63. PubMed ID: 7995053 [No Abstract] [Full Text] [Related]
3. Clonogenic assays for gynecologic malignancies. Methodology and results. EORTC Preclinical Therapeutic Models Groups (PTMG). Aapro MS Contrib Gynecol Obstet; 1994; 19():24-9. PubMed ID: 7995050 [No Abstract] [Full Text] [Related]
4. In vivo chemosensitivity test models for gynecologic malignancies. Methodology and results. Kleine W Contrib Gynecol Obstet; 1994; 19():76-81. PubMed ID: 7995055 [No Abstract] [Full Text] [Related]
5. Evaluation of new drugs and combinations in gynecologic tumors and cancer cell lines with the ATP-cell viability assay. Untch M; Sevin BU Contrib Gynecol Obstet; 1994; 19():145-55. PubMed ID: 7995046 [No Abstract] [Full Text] [Related]
6. Short-term assay (radiolabeled DNA-precursor uptake method) in gynecologic malignancies. Methodology and results. Petru E; Kaufmann M Contrib Gynecol Obstet; 1994; 19():30-8. PubMed ID: 7995051 [No Abstract] [Full Text] [Related]
7. Review of data on gynecologic cancer cell lines: potential applications of ATP-cell viability assays. Nguyen HN; Sevin BU; Perras JP; Averette HE Contrib Gynecol Obstet; 1994; 19():132-44. PubMed ID: 7995045 [No Abstract] [Full Text] [Related]
8. Prediction of drug resistance in cancer chemotherapy: the Kern and DiSC assays. Weisenthal LM; Kern DH Oncology (Williston Park); 1991 Sep; 5(9):93-103; disc. 104, 111-4, 117-8. PubMed ID: 1835882 [TBL] [Abstract][Full Text] [Related]
9. TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies. Andreotti PE; Linder D; Hartmann DM; Cree IA; Pazzagli M; Bruckner HW J Biolumin Chemilumin; 1994; 9(6):373-8. PubMed ID: 7879653 [TBL] [Abstract][Full Text] [Related]
10. ATP-cell viability assay methodology in both fresh gynecologic tumors and cell lines. Köchli OR; Perras JP; Sevin BU Contrib Gynecol Obstet; 1994; 19():108-21. PubMed ID: 7995042 [No Abstract] [Full Text] [Related]
11. The fluorescent cytoprint assay: a new approach to in vitro chemosensitivity testing. Meitner PA Oncology (Williston Park); 1991 Sep; 5(9):75-81; discussion 81-2, 85, 88. PubMed ID: 1835881 [TBL] [Abstract][Full Text] [Related]
12. [In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures]. Nakagawa T; Takahashi H; Kamiyama T; Nakanishi K; Takahashi M; Watanabe K; Taguchi K; Tsukahara M; Nakajima H; Kamachi H; Kurauchi N; Kamiyama N; Khor LW; Abumiya K; Matsushita M; Kobayashi H; Todo S Gan To Kagaku Ryoho; 2004 Dec; 31(13):2145-9. PubMed ID: 15628760 [TBL] [Abstract][Full Text] [Related]
13. Current status and future directions of chemosensitivity testing. Sevin BU; Perras JP; Köchli OR Contrib Gynecol Obstet; 1994; 19():179-94. PubMed ID: 7995049 [No Abstract] [Full Text] [Related]
14. Clinical correlations for cell culture assays based on the concept of total tumor cell kill. Weisenthal LM Contrib Gynecol Obstet; 1994; 19():82-90. PubMed ID: 7995056 [No Abstract] [Full Text] [Related]
15. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Hunter EM; Sutherland LA; Cree IA; Dewar JA; Preece PE; Wood RA; Linder D; Andreotti PE Eur J Surg Oncol; 1993 Jun; 19(3):242-9. PubMed ID: 8314382 [TBL] [Abstract][Full Text] [Related]
16. Anticancer chemosensitivity profiles of human breast cancer cells assessed by in vitro DNA synthesis inhibition assay. Nio Y; Tamura K; Kan N; Inamoto T; Ohgaki K; Kodama H Anticancer Res; 2000; 20(2B):1237-44. PubMed ID: 10810427 [TBL] [Abstract][Full Text] [Related]
17. [The present of drug sensitivity test]. Udagawa Y; Nozawa S Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):751-60. PubMed ID: 8808844 [No Abstract] [Full Text] [Related]
18. [Chemotherapy of malignant gynecologic neoplasms]. Huber R; Lau HU Zentralbl Gynakol; 1970 Jul; 92(30):966-70. PubMed ID: 5477142 [No Abstract] [Full Text] [Related]
19. An overview of chemosensitivity testing. Blumenthal RD Methods Mol Med; 2005; 110():3-18. PubMed ID: 15901922 [TBL] [Abstract][Full Text] [Related]
20. Chemosensitivity and chemoresistance testing in ovarian cancer. Cree IA Curr Opin Obstet Gynecol; 2009 Feb; 21(1):39-43. PubMed ID: 19125002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]